Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are in vivo molecular imaging methods which are widely used in nuclear medicine for diagnosis and treatment follow-up of many major diseases. These methods use target-specific molecules as probes, which are labeled with radionuclides of short half-lives that are synthesized prior to the imaging studies. These probes are called radiopharmaceuticals. The use of PET and SPECT for brain imaging is of special significance since the brain controls all the body’s functions by processing information from the whole body and the outside world. It is the source of thoughts, intelligence, memory, speech, creativity, emotion, sensory functions, motion control, and other important body functions. Protected by the skull and the blood–brain barrier, the brain is somehow a privileged organ with regard to nutrient supply, immune response, and accessibility for diagnostic and therapeutic measures. Invasive procedures are rather limited for the latter purposes. Therefore, noninvasive imaging with PET and SPECT has gained high importance for a great variety of brain diseases, including neurodegenerative diseases, motor dysfunctions, stroke, epilepsy, psychiatric diseases, and brain tumors. This Special Issue focuses on radiolabeled molecules that are used for these purposes, with special emphasis on neurodegenerative diseases and brain tumors.

SV2A --- SV2B --- SV2C --- microPET --- [18F]UCB-H --- epilepsy --- PBIF --- distribution volume --- blocking assay --- preclinical imaging --- Alzheimer’s disease (AD) --- network measure --- graph theory --- brain network --- positron emission tomography (PET) --- persistent homology --- Phosphodiesterase 2A (PDE2A) --- Positron Emission Tomography (PET) --- Benzoimidazotriazine (BIT) --- fluorinated --- Mouse Liver Microsomes (MLM) --- cyclic nucleotide phosphodiesterase --- PDE2A radioligand --- nitro-precursor --- fluorine-18 --- in vitro autoradiography --- PET imaging --- opioid receptors --- positron emission tomography --- radiotracers --- μOR-, δOR-, κOR- and ORL1-ligands --- movement disorders --- pain --- drug dependence --- GBM --- biomarkers --- Sigma 1 --- Sigma 2 --- PD-L1 --- PARP --- IDH --- Alzheimer’s disease --- Parkinson’s disease --- β-amyloid plaques --- neurofibrillary tangles --- α-synucleinopathy --- diagnostic imaging probes --- orexin receptors --- PET --- radiotracer --- imaging --- alpha 7 --- nicotinic acetylcholine receptors --- nAChR --- autoradiography --- amino acid --- FET --- FACBC --- FDOPA --- immunoPET --- molecular imaging --- glioma --- brain metastases --- adenosine A2A receptor --- rotenone-based mouse model --- [18F]FESCH --- two-step one-pot radiosynthesis

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.

polycythemia --- peptide receptor radiotherapy --- n/a --- vasculogenesis --- catecholamines --- neuroendocrine --- GTV --- adaptive immunity --- therapy resistance --- histology --- transgenic mice --- cryoablation --- spheroids --- energy metabolism --- somatostatinoma --- angiogenesis --- pheochromocytoma --- SDHD --- percutaneous ethanol injection --- metanephrines --- SDHB --- global longitudinal strain --- mutation --- normetanephrines --- catecholamine --- PASS --- PGL --- 177Lu-DOTATATE --- chromosomal alteration --- speckle-tracking echocardiography --- lL-6 --- dog --- percutaneous ablation --- stem-like tumor cells --- EPAS1 --- neural crest --- fluorescence imaging --- neutrophil --- xenograft --- inflammation --- head and neck --- weighted standard deviation --- FGF21 --- calorimetry --- HIF --- average real variability --- next-generation sequencing --- adrenocortical carcinoma --- carotid body --- hypoxia-inducible factor --- paraganglioma --- succinate dehydrogenase --- blood pressure variability --- arrhythmia --- mortality --- NF1 --- toll-like receptor --- GAPP --- NET --- subclinical systolic dysfunction --- pheochromocytoma and paraganglioma --- PET-CT --- pan-cancer analysis --- mouse pheochromocytoma cells --- innate immunity --- neurogenesis --- neuroendocrine tumor --- obesity --- hypotension --- hypoxia --- CNV detection --- 18F-FDOPA --- comparative genomics --- adrenomedullary function --- PCC --- pathogen-associated molecular patterns --- adrenal tumor --- radiotherapy --- 11C-hydroxy-ephedrine --- radiofrequency ablation --- PPGL --- minimally invasive procedure --- sporadic --- diabetes mellitus --- adrenal incidentaloma --- germline mutation --- immunotherapy --- VHL --- immunohistochemistry --- metastatic OR malignant pheochromocytoma --- erythropoietin --- postoperative --- targeted therapy --- PRRT --- metastatic --- mitochondria --- T cell --- TCA cycle --- meta-analysis --- pseudohypoxia --- ectopic secretion --- radiosensitization --- chromogranin A --- hereditary --- hypertension --- PET --- phosphorylation tyrosine hydroxylase